- Report
- May 2024
- 137 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- February 2025
- 240 Pages
Global
From €2572EUR$2,690USD£2,153GBP
- Report
- April 2025
- 93 Pages
Global
From €5354EUR$5,600USD£4,482GBP
- Report
- April 2025
- 92 Pages
Global
From €5354EUR$5,600USD£4,482GBP
- Report
- July 2024
- 175 Pages
Global
From €4780EUR$5,000USD£4,002GBP
- Report
- March 2025
- 150 Pages
Global
From €4637EUR$4,850USD£3,882GBP
- Report
- July 2024
- 200 Pages
Global
From €4732EUR$4,949USD£3,961GBP
- Report
- January 2024
- 395 Pages
Global
From €7171EUR$7,500USD£6,002GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1434EUR$1,500USD£1,200GBP
- Report
- January 2024
- 197 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Report
- October 2023
- 178 Pages
Global
From €4302EUR$4,500USD£3,601GBP
- Report
- November 2023
- 381 Pages
Global
€4776EUR$4,995USD£3,998GBP
- Report
- November 2021
- 844 Pages
Global
From €4780EUR$5,000USD£4,002GBP
- Book
- November 2023
North America

Within the sector of central nervous system (CNS) drugs, the market for drugs targeting drug-resistant epilepsy represents a specialized niche aimed at addressing the needs of patients who do not respond adequately to standard antiepileptic medications. Drug-resistant epilepsy, also known as refractory epilepsy, is characterized by recurrent seizures that cannot be controlled with traditional treatments. The development of CNS drugs for this condition focuses on novel mechanisms of action and advanced drug delivery systems to enhance efficacy and minimize side effects.
The CNS drug industry for drug-resistant epilepsy is driven by ongoing research and development efforts to discover new therapeutic targets and formulations. This includes the study of neurotransmitter systems, ion channels, and genetic factors that contribute to the ineffectiveness of standard epilepsy treatments. Companies in this market invest in clinical trials and collaboration with medical communities to ensure that emerging treatment options can meet the stringent regulatory standards and address unmet medical needs in neurology.
Some companies actively engaged in the drug-resistant epilepsy market include Novartis, Pfizer, UCB Pharma, Eisai, GW Pharmaceuticals, and Takeda Pharmaceutical Company. These companies contribute through innovative research and development programs aimed at enhancing the quality of life for patients with refractory seizures by providing new, more effective treatment options. Show Less Read more